These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21500870)

  • 21. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis.
    Crayne CB; Beukelman T
    Pediatr Clin North Am; 2018 Aug; 65(4):657-674. PubMed ID: 30031492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Kröger L; Aalto K; Lahdenne P
    Pediatr Rheumatol Online J; 2019 Dec; 17(1):80. PubMed ID: 31842940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind.
    Scott C; Chan M; Slamang W; Okong'o L; Petty R; Laxer RM; Katsicas MM; Fredrick F; Chipeta J; Faller G; Pileggi G; Saad-Magalhaes C; Wouters C; Foster HE; Kubchandani R; Ruperto N; Russo R
    Clin Rheumatol; 2019 Feb; 38(2):563-575. PubMed ID: 30267356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.
    Kemper AR; Van Mater HA; Coeytaux RR; Williams JW; Sanders GD
    BMC Pediatr; 2012 Mar; 12():29. PubMed ID: 22420649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasound in juvenile idiopathic arthritis.
    Magni-Manzoni S
    Pediatr Rheumatol Online J; 2016 May; 14(1):33. PubMed ID: 27234966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate for treating juvenile idiopathic arthritis.
    Takken T; Van der Net J; Helders PJ
    Cochrane Database Syst Rev; 2001; 2001(3):CD003129. PubMed ID: 11687037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Children with Juvenile Idiopathic Arthritis.
    Viswanathan V; Murray KJ
    Indian J Pediatr; 2016 Jan; 83(1):63-70. PubMed ID: 26639461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
    Brunner HI; Wong R; Nys M; Kou TD; Dominique A; Martini A; Lovell DJ; Ruperto N;
    Paediatr Drugs; 2020 Dec; 22(6):653-672. PubMed ID: 33029724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].
    Horneff G
    Z Rheumatol; 2005 Jun; 64(5):317-26. PubMed ID: 15965816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of disease activity in a low-income juvenile idiopathic arthritis cohort.
    Rocha FAC; Landim JIVD; Aguiar MG; Accioly JPE; Lechiu CN; Costa LHA; Júnior CNR; da Rocha LN; Rocha HAL
    Rheumatol Int; 2019 Jan; 39(1):67-71. PubMed ID: 30101369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.
    Griffin TA; Barnes MG; Ilowite NT; Olson JC; Sherry DD; Gottlieb BS; Aronow BJ; Pavlidis P; Hinze CH; Thornton S; Thompson SD; Grom AA; Colbert RA; Glass DN
    Arthritis Rheum; 2009 Jul; 60(7):2113-23. PubMed ID: 19565504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials.
    Cabrera N; Avila-Pedretti G; Belot A; Larbre JP; Mainbourg S; Duquesne A; Janiaud P; Kassai B; Cucherat M; Lega JC
    Rheumatology (Oxford); 2020 Sep; 59(9):2226-2236. PubMed ID: 32449926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Juvenile Idiopathic Arthritis.
    Barut K; Adrovic A; Şahin S; Kasapçopur Ö
    Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.
    Hayward K; Wallace CA
    Arthritis Res Ther; 2009; 11(1):216. PubMed ID: 19291269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
    Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations for the use of methotrexate in juvenile idiopathic arthritis.
    Niehues T; Lankisch P
    Paediatr Drugs; 2006; 8(6):347-56. PubMed ID: 17154642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Juvenile arthritides].
    Horneff G
    Z Rheumatol; 2010 Oct; 69(8):719-35; quiz 736-7. PubMed ID: 20798949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Klotsche J; Minden K; Niewerth M; Horneff G
    Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.